In an analysis of a cohort of 250 primary triple-negative breast cancer samples from eight clinically annotated gene expression datasets, triple-negative breast cancer patients with low expression levels of SHARP1 and CCNG2 had a significantly higher probability of developing metastases and of reduced survival [33]. This evidence concerns the gene CCNG2 and triple-negative breast carcinoma.